Rapid access to enabling technologies

Rapid access to enabling technologies for SARS-CoV-2 Main Protease related drug discovery

 

Dear Customer,

 

our industry is very engaged in COVID-19 related activities.

In that regard, Proteros is also highly committed to quickly establish enabling technologies for accelerating novel small molecule inhibitors of SARS-CoV-2 Main Protease

- structure solution (x-ray crystallography) of SARS-CoV-2 Main Protease-Ligand complexes in rapid access mode

- biophysical and biochemical services to study  SARS CoV-2 Main Protease-Ligand interactions in terms of affinity, on/off rates, residence time, thermostability and inhibition for hit finding and hit optimization in drug discovery programs

- high quality recombinant protein supply

 

In the context of ligand structure analysis, we would like to mention that we have continued weekly access to Swiss Light Source (SLS) beamline PXII.

 

Please contact us to discuss in more detail how we can help you in the course of your project.

 

Best regards,

 

Torsten Neuefeind, CEO, and Proteros Team